Development of Theranostic Cationic Liposomes Designed for Image-Guided Delivery of Nucleic Acid.
MRI
magnetic cationic liposome
magnetic targeting
magnetofection
nucleic acid delivery
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
08 Sep 2020
08 Sep 2020
Historique:
received:
07
07
2020
revised:
21
08
2020
accepted:
01
09
2020
entrez:
11
9
2020
pubmed:
12
9
2020
medline:
12
9
2020
Statut:
epublish
Résumé
Cationic liposomes have been considered as potential vectors for gene delivery thanks to their ability to transfect cells with high efficiency. Recently, the combination of diagnostic agent and therapeutic agents in the same particle to form a theranostic system has been reported. Magnetic liposomes are one of these examples. Due to the magnetic nanoparticles encapsulated in the liposomes, they can act as a drug delivery system and, at the same time, a magnetic resonance imaging contrast enhancement agent or hyperthermia. In this work, nucleic acid delivery systems based on magnetic cationic liposomes (MCLs) were developed. Two different techniques, reverse phase evaporation and cosolvent sonication, were employed for liposome preparation. Both strategies produced MCLs of less than 200 nm with highly positive charge. Enhancement of their transverse and longitudinal relaxivities
Identifiants
pubmed: 32911863
pii: pharmaceutics12090854
doi: 10.3390/pharmaceutics12090854
pmc: PMC7559777
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Langmuir. 2012 Aug 14;28(32):11834-42
pubmed: 22799267
Curr Med Chem. 2003 Jul;10(14):1263-77
pubmed: 12678798
Mol Imaging Biol. 2019 Apr;21(2):269-278
pubmed: 29942990
BMC Pharmacol Toxicol. 2018 Jul 11;19(1):43
pubmed: 29996945
Bioorg Med Chem. 2009 Apr 15;17(8):2950-62
pubmed: 19299149
Int J Pharm. 2009 Jan 21;366(1-2):211-7
pubmed: 18848871
PLoS One. 2014 Mar 27;9(3):e92924
pubmed: 24675979
Methods Mol Biol. 2019;1943:123-139
pubmed: 30838613
Chem Rev. 2012 Nov 14;112(11):5818-78
pubmed: 23043508
J Control Release. 2006 Aug 10;114(1):100-9
pubmed: 16831482
J Med Chem. 1998 Jan 15;41(2):229-35
pubmed: 9457245
Science. 1993 May 14;260(5110):926-32
pubmed: 8493530
Pharm Res. 2002 Aug;19(8):1144-9
pubmed: 12240940
Nanomaterials (Basel). 2017 Apr 28;7(5):
pubmed: 28452950
Proc Natl Acad Sci U S A. 1991 Apr 15;88(8):3155-9
pubmed: 2014235
Cancer Res. 1995 Sep 1;55(17):3752-6
pubmed: 7641188
Pharmaceutics. 2013 Oct 25;5(4):542-69
pubmed: 24300562
Proc Natl Acad Sci U S A. 1998 Apr 14;95(8):4607-12
pubmed: 9539785
Ther Deliv. 2013 Apr;4(4):421-3
pubmed: 23557281
Nature. 2015 Jul 2;523(7558):92-5
pubmed: 25970250
Biochim Biophys Acta. 2004 Jan 28;1660(1-2):41-52
pubmed: 14757219
J Control Release. 2017 Sep 28;262:170-181
pubmed: 28710005
3 Biotech. 2018 Jun;8(6):279
pubmed: 29881657
J Gene Med. 2010 Apr;12(4):323-32
pubmed: 20209487
Drug Deliv Transl Res. 2013 Dec;3(6):499-503
pubmed: 24932437
J Gene Med. 2000 Jan-Feb;2(1):32-40
pubmed: 10765503
Nat Nanotechnol. 2009 Sep;4(9):598-606
pubmed: 19734934
N Engl J Med. 1990 Aug 30;323(9):570-8
pubmed: 2381442
J Gene Med. 2018 May;20(5):e3015
pubmed: 29575374
J Gene Med. 2004 Feb;6 Suppl 1:S24-35
pubmed: 14978748
Biochim Biophys Acta. 2012 Nov;1818(11):2801-7
pubmed: 22766474
Int J Pharm. 2014 Jan 1;459(1-2):70-83
pubmed: 24286924
Int J Nanomedicine. 2011;6:2275-83
pubmed: 22072865
Int J Mol Sci. 2016 Jul 27;17(8):
pubmed: 27472319
Biol Chem. 2003 May;384(5):737-47
pubmed: 12817470
J Control Release. 2013 Jan 10;165(1):1-8
pubmed: 23123257
Nano Lett. 2013 Mar 13;13(3):1059-64
pubmed: 23394319
J Control Release. 2011 Jun 30;152(3):393-401
pubmed: 21497175
J Control Release. 2004 Jan 8;94(1):1-14
pubmed: 14684267
Jpn J Cancer Res. 1996 Nov;87(11):1179-83
pubmed: 9045948
Eur J Pharm Biopharm. 2015 Feb;90:63-9
pubmed: 25448076
Bioconjug Chem. 2005 May-Jun;16(3):608-14
pubmed: 15898728
Science. 1995 Oct 20;270(5235):475-80
pubmed: 7570001